Selskabets formål er at drive handel og produktion af farmaceutiske produkter og alle aktiviteter, der relaterer sig til research, udvikling, produktion, udnyttelse og marketing af bio-farmaceutiske og farmaceutiske produkter, inklusive vacciner, serummer, immummodulatoer og produkter afledt fra bio-teknologi og højteknologi beregnet til humanmedicinske lægemidler.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2024 | 452.6 mio. | 6.2 mio. | 192 mio. | 53.6 mio. | 81 | |
CVR: 19064301
Secondary names: AVENTIS A/S, RHONE-POULENC RORER A/S, HOECHST MARION ROUSSEL A/S
Compared to 406 companies in Engroshandel med medicinalvarer og sygeplejeartikler
Comparison is based on industry median values
Sanofi A/S is experiencing a declining trend in revenue and profitability, with 2024 revenue at 452.6 million DKK and a profit of 6.2 million DKK, down from 527.6 million DKK and 3.7 million DKK in 2023. The company’s equity has shown a gradual increase, reaching 53.6 million DKK in 2024, but this is accompanied by a significant drop in profit margins from 21.9 million DKK in 2021 to just 6.2 million DKK in 2024. The declining revenue and profit suggest potential challenges in maintaining its competitive position within the pharmaceutical wholesale industry. Overall, while the equity position is relatively stable, the decreasing profitability raises concerns about future financial health.
AI-generated summary
Companies in the same industry and area
CVR 16938106
CVR 27293972
CVR 33860463
CVR 35234748
CVR 39762560
companydata.dk